URGN CIK: 1668243

UroGen Pharma Ltd.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
114
FY22:
129
FY23:
169
FY24:
276
FY25:
186
(positive)
Change from FY21 to FY25
millions USD
FY21:
5.36
FY22:
6.71
FY23:
9.13
FY24:
9.58
FY25:
14.4
Total assets
Change from FY21 to FY25
millions USD
FY21:
120
FY22:
136
FY23:
178
FY24:
286
FY25:
200

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
22.4
FY22:
23.9
FY23:
31.2
FY24:
45.9
FY25:
46.4
(negative)
Change from FY21 to FY25
millions USD
FY21:
89.0
FY22:
201
FY23:
212
FY24:
249
FY25:
260
(positive)
Change from FY21 to FY25
millions USD
FY21:
8.41
FY22:
−89.4
FY23:
−65.2
FY24:
−8.80
FY25:
−105
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
120
FY22:
136
FY23:
178
FY24:
286
FY25:
200

All amounts in millions USD Data source:SEC EDGAR